{rfName}
Ef

Indexed in

License and use

Icono OpenAccess

Citations

37

Altmetrics

Grant support

This study was funded by the Barcelona Magic Line fundraising program to C.L. J.C.J.-C. and D.S.-I. are Miguel Servet investigators (Carlos III National Institute of Health, Spain).

Analysis of institutional authors

Ramon, DanielAuthor

Share

June 18, 2024
Publications
>
Article
Sí

Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial

Publicated to:Nutrients. 12 (10): 3123-14 - 2020-10-01 12(10), DOI: 10.3390/nu12103123

Authors: Amat-Bou, Montse; Garcia-Ribera, Sonika; Climent, Eric; Piquer-Garcia, Irene; Corripio, Raquel; Sanchez-Infantes, David; Villalta, Laia; Elias, Maria; Jimenez-Chillaron, Josep C; Chenoll, Empar; Ramon, Daniel; Ibanez, Lourdes; Ramon-Krauel, Marta; Lerin, Carles

Affiliations

Archer Daniels Midland Co Biopolis, Valencia 46980, Spain - Author
Germans Trias & Pujol Res Inst, Dept Endocrinol & Nutr, Barcelona 08916, Spain - Author
Hosp St Joan de Deu, Barcelona 08950, Spain - Author
Hosp St Joan de Deu, Child & Adolescent Psychiat & Psychol Dept, Barcelona 08950, Spain - Author
Inst Recerca St Joan de Deu, Barcelona 08950, Spain - Author
Inst Salud Carlos III, CIBERDEM, Madrid 28029, Spain - Author
Inst Salud Carlos III, CIBERobn, Madrid 28029, Spain - Author
Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Serv Pediat Endocrinol, Inst Invest & Innovacio Parc Tauli I3PT, Sabadell 08208, Spain - Author
See more

Abstract

Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1 ' s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo-BPL1 (n = 19) or BPL1-placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480).

Keywords

AdultAxisBrainCect 8145GlucoseGut microbiotaHyperphagiaInsulin sensitivityManagementMental healtMental healthMetabolismObeseObesityOverweightPrader&#8211Prader–willi syndromeProbiotic supplementationWilli syndrome

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Nutrients due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position 17/88, thus managing to position itself as a Q1 (Primer Cuartil), in the category Nutrition & Dietetics.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 7.44, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-23, the following number of citations:

  • WoS: 15
  • Scopus: 17

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-23:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 200.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 204 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 8.85.
  • The number of mentions on the social network X (formerly Twitter): 6 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.